Laboratorios Richmond SACIF - Asset Resilience Ratio
Laboratorios Richmond SACIF (RICH) has an Asset Resilience Ratio of 0.22% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Laboratorios Richmond SACIF to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Laboratorios Richmond SACIF's Asset Resilience Ratio has changed over time. See Laboratorios Richmond SACIF (RICH) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Laboratorios Richmond SACIF's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Laboratorios Richmond SACIF (RICH) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AR$0.00 | 0% |
| Short-term Investments | AR$778.82 Million | 0.22% |
| Total Liquid Assets | AR$778.82 Million | 0.22% |
Asset Resilience Insights
- Limited Liquidity: Laboratorios Richmond SACIF maintains only 0.22% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Laboratorios Richmond SACIF Industry Peers by Asset Resilience Ratio
Compare Laboratorios Richmond SACIF's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Bausch Health Companies Inc
TO:BHC |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.15% |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Hainan Haiyao Co Ltd
SHE:000566 |
Drug Manufacturers - Specialty & Generic | 3.27% |
|
Shanxi Zhendong Pharmaceutical
SHE:300158 |
Drug Manufacturers - Specialty & Generic | 10.74% |
Annual Asset Resilience Ratio for Laboratorios Richmond SACIF (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Laboratorios Richmond SACIF.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.13% | AR$2.95 Billion ≈ $2.13 Million |
AR$260.15 Billion ≈ $188.25 Million |
+1.01pp |
| 2023-12-31 | 0.12% | AR$404.16 Million ≈ $292.45K |
AR$337.32 Billion ≈ $244.09 Million |
-3.40pp |
| 2022-12-31 | 3.52% | AR$1.43 Billion ≈ $1.04 Million |
AR$40.72 Billion ≈ $29.47 Million |
-6.96pp |
| 2021-12-31 | 10.48% | AR$2.69 Billion ≈ $1.95 Million |
AR$25.69 Billion ≈ $18.59 Million |
+6.23pp |
| 2020-12-31 | 4.25% | AR$345.71 Million ≈ $250.16K |
AR$8.13 Billion ≈ $5.89 Million |
+4.22pp |
| 2019-12-31 | 0.03% | AR$1.72 Million ≈ $1.24K |
AR$5.13 Billion ≈ $3.72 Million |
+0.02pp |
| 2018-12-31 | 0.02% | AR$480.78K ≈ $347.90 |
AR$2.71 Billion ≈ $1.96 Million |
-0.15pp |
| 2017-12-31 | 0.16% | AR$2.56 Million ≈ $1.85K |
AR$1.55 Billion ≈ $1.12 Million |
-0.73pp |
| 2016-12-31 | 0.89% | AR$7.67 Million ≈ $5.55K |
AR$861.13 Million ≈ $623.12K |
+0.80pp |
| 2015-12-31 | 0.09% | AR$494.37K ≈ $357.73 |
AR$532.83 Million ≈ $385.56K |
-0.30pp |
| 2014-12-31 | 0.39% | AR$1.51 Million ≈ $1.09K |
AR$385.66 Million ≈ $279.06K |
-0.18pp |
| 2013-12-31 | 0.58% | AR$1.66 Million ≈ $1.20K |
AR$287.37 Million ≈ $207.94K |
-0.90pp |
| 2012-12-31 | 1.47% | AR$3.99 Million ≈ $2.89K |
AR$270.95 Million ≈ $196.06K |
+1.43pp |
| 2011-12-31 | 0.04% | AR$60.00K ≈ $43.42 |
AR$159.03 Million ≈ $115.07K |
-- |
About Laboratorios Richmond SACIF
Laboratorios Richmond S.A.C.I.F., a pharmaceutical company, develops and manufactures pharmaceutical products. It provides antiretroviral products for the treatment of human immunodeficiency virus (HIV); oncology and oncohematology drugs; cardiometabolic drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs … Read more